
Index

- Abbott, F.M. 78, 237, 271, 272
Abraham, J. 77
Aiken case 195–6, 204
Andorra 84
Anti-counterfeiting Trade Agreement (ACTA) 24, 78
antitrust immunity, and intellectual property rights 78
Apostolopoulos, H. 78
appellation of origin 123
Argentina
 burden of proof in process patent infringement cases 224–5
 changes to patents regime 217
 compulsory licenses 218–19
 copyright laws 9
 exclusive marketing rights 219–22
 GMO soybean meal 46
 import restrictions 222–3
 injunctive relief 79
 parallel imports 223
 patentability
 criteria in law 228
 of micro-organisms 227–9
 preliminary injunctions 225–7
 product by process patent protection 223–4
 protection of test data against unfair commercial use 230–31
 transitional patents 229–30
 USA patent dispute 216–31
Argentina – Patent Protection for Pharmaceuticals and Test Data Protection for Agricultural Chemicals 104, 227
Armenia 93
audiovisual works 8
Australia 20, 104–5
 geographical indications 129, 130
Bahamas 84
‘A Balanced Interpretation of the “Three-step Test” in Copyright Law’ 281
Bartels, L. 18
Beckerman-Rodau, A. 75
Berne Convention for the Protection of Literary and Artistic Works 4, 14
 minor exceptions doctrine 200
 and TRIPS 197–8, 242, 244
Bhagwati, J. 287
Bhuiyan, S. 294
Biadgleng, E. 34, 60
bilateral agreements 9, 18, 106
bioequivalence 261
Blenko, W.J. 45
border measures 25
 comparison of
 SECURE and TRIPS 29–30, 34
 UPU Resolution 40 and TRIPS 36–7
 implications of broad 42–6
 under the TRIPS Agreement 25–8
 UPU 35–6
 WCO 28–9
Boyle, J. 280
Brazil 89
 compulsory licenses 235
 HIV/AIDS programme 233
 industrial property law 232, 234
 USA patent dispute 232–7
Brazil – Measures Affecting Patent Protection 232
Brussels Conference 199, 200, 201
Burk, D.L. 48
Cambodia 107, 108, 111
 accession to WTO 110
 administration of law 115
 data protection 105, 106
 stand-still principle 111
Canada
 Patent Law 239
 pharmaceutical inventions 240
Canada – Generics 271
Canada – Patent Protection of Pharmaceutical Products 14, 21, 23, 191–2, 237–82

- application of
 - TRIPS Article 27.1 252–3
 - TRIPS Articles 28 and 30 in
 - stockpiling exception case 242–3
- burden of proof, issues on 241–2
- compatibility of Canadian Patent Law with TRIPS 237
- difference between regulatory
 - approval and stockpiling 265–70
- discrimination as to the field of technology 255–7
- impact on clinical test data 263–5
- implications for
 - domestic legislation 267–70
 - generic producers 258–63
- legitimate interests 249–52
- limited exception requirement 244, 245, 246, 247, 253, 262, 263
- normal exploitation 247–9, 277, 279
- regulatory review exception 238, 246, 249, 267, 270
- rules of interpretation 241–2
- stockpiling exception of Patent Act 238, 241, 242–3, 245, 246, 262, 274, 275, 279
- and the Three-step test 270–71, 279
- WTO panel analysis 213
- Cape Verde 107, 108, 114
 - accession to WTO 110
 - commitments 112–13
 - stand-still principle 111
- Carroll, M.W. 48, 49, 63, 68, 74
- Carter, B.E. 293
- Carvalho, N.P. de 221, 274, 275
- Chapman, M. 55
- Charlier, C. 139, 287
- Chicago Convention on International Civil Aviation (1944), Article 27 273, 275
- Chile 213
- China 92, 93, 94, 107
 - administration of law 114–15
 - criminal procedure to enforce IPR 97–8, 99
 - data protection 105–6
 - enforcement of IPRs 108
 - implementation of TRIPS 94–7
 - review of administrative decisions and right of appeal 115–16
 - unfair use of data 105
- China – Measures Affecting Imports of Automobile Parts* 118–19
- China – Measures Affecting the Protection and Enforcement of Intellectual Property Rights* 100, 104
- Chinese Taipei 92, 93–4, 107
 - administration of law 115
 - alcohol and tobacco 108
- Coco, R. 78
- collective management organizations (CMOs) 206, 207
- commercial-scale counterfeiting and piracy 99–100
- compensatory liability regimes 260
- compulsory licenses 56, 58, 59–60
 - Argentina 218–19
 - Brazil 235
 - opposition to 75–6
- computer programs 14
- Continental Paper Bag Co v. Eastern Paper Bag Co.* 52, 53–4
- contracting parties 4
- ‘convoyed’ sales 62
- copyright 50, 73–4, 276
 - and digital technology 212
 - exceptions and limitations 213
 - irreparable harm 66
 - purpose 192
 - refusal of injunctions 52–3
- copyright law 9
 - Three-step test 281
- Cornish, W.R. 123
- Correa, C. 46, 107, 221, 236, 277, 286
- Cottier, T. 286
- ‘counterfeit’, IMPACT definition 38–9
- ‘counterfeit medical products’ 37
 - definition 42
- counterfeiting 5, 26, 42, 99
- Crews, K. 213
- criminal enforcement, IPRs 97–8
- Cuba 283, 289
 - US – Section 211 Appropriations Act of 1998* 283–97
- customs administrations
 - expansion of authority 40–41, 42
 - implications 44–6

- damages
 - assessing adequacy 61–6
 - non-practising entities 63–5
 - practising entities 61–3
- Dannay, R. 56, 64
- DaSilva, R.J. 64
- data, protection of undisclosed
 - pharmaceutical and agrochemical test data 101–7
- ‘data exclusivity’ 106, 231
- databases 8
- ‘Declaration’ on ‘A Balanced Interpretation of the “Three-step test” in Copyright Law’ 272
- developed countries 83
- developing countries 5, 83–4
 - and geographical indications 129
 - and SECURE 29–30
 - standards 7
- digital technology, and copyright 212
- Dinwoodie, G.B. 9, 11, 14
- discretionary legislation 294–6
- discrimination
 - de facto 256–7, 267
 - de jure 256, 267
 - meaning of term 255–6
 - term in TRIPS 269
- Disney, H. 381
- dispute settlement 4–5
 - interpretation principles 19
 - parallel imports 19–20
 - under TRIPS 215–36
- disputes
 - USA–Argentina patent dispute 216–31
 - USA–Brazil patent dispute 232–7
- ‘diverted’ sales 62
- Doctrine of Equivalents 45
- Doha Declaration on the TRIPS Agreement and Public Health 10, 233, 271, 280
- Doha Round 97, 123, 128
 - implementation issues 129
- domestic law 7
 - implications of *Canada – Patent Protection of Pharmaceutical Products* 267–70
 - patent exceptions 272
- Drahos, P. 6, 65
- Dratler, J. 76
- Dreyfuss, R. 9, 11, 14
- eBay Inc. v. MercExchange LLC* 53–4, 56, 74
 - right-remedy distinction 54
- EC – GIs* case 130–35
 - findings under GATT 133–4
 - implementation of panel findings 135–7
 - protection of pre-existing trademarks 134–5
- Economides, N. 76
- Ecuador 91
- Ellis, D. 55, 66
- emerging markets 83–4
- ‘entire market value’ rule 68
- Epstein, R.A. 76
- equitable jurisprudence, injunctive remedies 61–77
- equity jurisprudence 48–9
- Europe, geographical indications 126, 127
- European Communities, and geographical indications 8, 122–40
- European Partnership Agreements (EPAs) 18
- European Patent Office (EPO) 263, 270
- exclusive marketing rights
 - Argentina 219–22
 - use of term 220–22
- exclusive rights 19
- exhaustion of rights 19
- experimental use exemption 262
- Fabricotti, A. 18
- Faunce, T.A. 77
- Fink, C. 263
- foreign vessels exception 273, 275
- France 126
- Frankel, S. 9, 10, 11
- Free Trade Agreements (FTAs) 16, 24, 263, 265
 - and intellectual property 9
 - intellectual property chapters 20
 - most favoured nation exemption 17–18
- G8 (Group of Eight) 25, 41
- Gad, M.O. 60

- Garnett, N. 213
 Garrison, C. 237, 258, 261, 262, 265, 266, 271, 272, 273, 275
 General Agreement on Tariffs and Trade (GATT) 23, 81, 118, 215–16, 294
 applicability of jurisprudence to interpretation of TRIPS 3–23
 disputes 3, 19
 EC – GIs case 133–4
 flexibilities 22
 geographical indications 122
 non-discrimination principles 13
 tariffs as acceptable trade barriers 6
 General Agreement on Trade in Services (GATS) 3, 5, 6
 chapeau 22
 non-discrimination principles 13
 generic manufacturing 106, 268
 generic producers 258–65
 Geneva Convention for the Protection of Producers of Phonograms against Unauthorized Duplication of their Phonograms (1971) 113
Geographical Indications 15
 geographical indications 8, 122
 Café de Columbia 138
 definition in TRIPS 124
 and developing countries 129
 disputes under TRIPS 128–30
 economic interests and production systems 126–7
 EU regulation (2006) 135–7
 Europe 126, 127
 as a form of intellectual property 124
 and trademarks 123, 139–40
 tradition and consumer perception 125–6
 and TRIPS 123–7
 and unfair competition 124–5
 see also EC – GIs case
 Gervais, D. 7, 17, 60
 Ginsburg, J.C. 18, 196
 Golec, J.H. 77
 Gorman, R.A. 196
 grandfathering (national exceptions) 199
 Grimmer, J.J. 117
 Hamilton, K. 63
 Handbook on Accession to the WTO 84
 Handler, M. 130, 138
 Hasenzahl, C. 76, 268
Havana Club 16
 Heald, P.J. 20
 Herbert, W.N. 76
 HIV/AIDS 233
 Holzmann 45
 Horn, H. 286
 Howse, R.L. 12, 286, 287, 288
 import restrictions, Argentina 222–3
 in-transit seizures 44
 India 268
 counterfeit drugs 42–3
 patent exceptions 258
 Indian Pharmaceuticals Export Promotion Council (Pharmexcil) 42
 infringement
 continuing 73, 75
 of intellectual property 51
 infringing activity, judicial discretion to deny injunctions to stop 49–3
 injunctions
 intellectual property 67
 judicial flexibility to deny 53–6
 monitoring 66
 ‘ongoing royalty’ 56
 patents 51–2
 signalling concerns 68
 to inhibit continued infringement 67
 injunctive relief 50, 51, 52, 66–7, 79
 domestic policy flexibility under TRIPS 57–60
 flexibility to deny 56
 four-factor test 61
 holdup-cost concerns 68
 and judicial resources 67
 national treatment 60
 and public interest 73–4
 regarding patent infringement 55
 injunctive remedies, equitable jurisprudence 61–77
 innovation 5, 7
 intellectual property
 enforcement law and standards, developed countries 25

- implications of broad definition 42–3
- increased standards 10–11
- infringement 51
- injunctions 67
- intellectual property protection
 - and barriers to trade 5–6
 - standards 7–8
- intellectual property rights
 - and antitrust immunity 78
 - commitments of countries acceding to WHO 87–114
 - criminal enforcement 97–8
 - enforcement 40
 - border measures 25
 - implications of expanded scope 43–4
 - expansion of scope of protection and enforcement 40
 - impact on public policy 280
 - and parallel imports 20
 - scope 8
- International Civil Aviation (Chicago)
 - exception 273
- International Convention for the Protection of Performers, Producers of Phonograms and Broadcasting Organizations (Rome Convention) 4
- international harmonization 293
 - and national treatment 295
- international intellectual property agreements 4
- International Medicinal Products Anti-counterfeit Taskforce (IMPACT) 24
- international treaties, rules for
 - interpretation 9
- irreparable harm 65
 - assessing potential for 61–6
 - copyright 66
 - presumption 50, 51, 52, 54
- Isaacs, D.H. 65
- Jackson, J. 19
- Jaffe, A.B. 278
- Japan – Tariff on Import of Spruce-Pine-Fir (SPF) Dimension Lumber* 13
- Japan – Taxes on Alcoholic Beverages* 3, 12, 15
- Jarosz, D.E.J. 55
- Jordan 92
- Joseph, L. 43
- Josling, T. 126
- judicial flexibility, to deny injunctions 53–6
- Keener Hughen, W. 77
- Keller, E. 63
- Laing, S. 128
- least-developed countries (LDCs) 83, 84
 - IP rights issues in accession to WTO 109–14
- legislation, mandatory and discretionary 294–6
- legitimate interests, meaning of term 249–52, 278
- Lemley, M.A. 48, 51, 68
- Lerner, J. 278
- Lewis, T. 260
- lex specialis* 15, 23
- Li, X. 25, 30
- liability rules, and property rules 65
- like products and services, notion 12, 13
- ‘limited’, definition of 271
- limited exception requirement 149, 244, 245, 246, 247, 253, 262, 263, 275, 276
- limited exceptions, meaning of term 244–6, 273, 274
- ‘linkage requirements’ 107
- Lisbon Agreement 124
- Macedonia 93
- Madrid Agreement 124
- ‘mailbox’ system, patents 220, 222
- mandatory and discretionary, legislation 294–6
- Marrakesh Agreement 3, 81
- Maskus, K.E. 260
- Mattson, J.E. 216
- Mavroidis, P.C. 286
- Max Planck Institute for Intellectual Property 214, 281
- Meir, P. 261
- Merck v. Integra lifesciences* 259, 261–2

- micro-organisms, patentability 227–9
- minor exceptions doctrine 198–200
- most-favoured nation 11–14, 84, 94, 255, 285, 293
 - in GATT and GATS 12
 - TRIPS' lack of exception 17–19
 - WTO panels and TRIPS 15–16
- Mueller, J.M. 268
- Munoz, V. 34

- national drug authorities (DRA) 261, 264
- national exceptions, grandfathering 199
- national treatment 11–14, 84, 131–3, 255, 285
 - in GATT and GATS 12
 - injunctive relief 60
 - and international harmonization 295
 - reciprocity 288
 - in TRIPS 287–8
 - and unilateralism 293–4
 - in *US – Section 211 Appropriations Act of 1998* 286–96
 - WTO panels and TRIPS 15–16
- Negro, S.C. 217
- Nepal 107, 108
 - accession to WTO 110, 113
 - administration of law 115
 - stand-still principle 111
- Neven, D.J. 286
- new world countries 122, 130
- New Zealand, copyright laws 9
- Ngo, M.A. 139, 287
- Nielsen, C.M. 75
- non-discrimination principles 13
- non-practising entities, damages 63–5, 68
- 'normal', interpretation of term in *US – Copyright* 279
- 'normal business losses' 66
- 'normal exploitation' 205–6, 277–8
 - meaning of term 247–9, 277
- North American Free Trade Agreement (NAFTA) 268

- OECD 269
- Oman 92
- 'ongoing royalty' injunctions 56, 59, 76

- Panama 92
- parallel imports 7, 19–20, 23, 223
 - and intellectual property rights 20
- Paris Convention for the Protection of Industrial Property 4, 102, 124, 283, 287
 - Article 2 286
 - Article 5 235–6
 - Article 5ter 273
 - Article 10bis 25, 103, 231
 - 'unfair commercial use' 231
- passing off doctrine 123
- patent exceptions 258, 275
 - under domestic law 272
- patent infringement
 - determination 45
 - injunctive relief 55
- patent law, traditional knowledge in 8
- patent rights
 - definition 221
 - in TRIPS 253
- patent rules, and technological developments 270
- patentability 14
 - micro-organisms 227–9
 - requirements 268–9
- patents 54, 77
 - assessment of damages 61–6
 - injunctions 51–2
 - 'mailbox' system 220, 222
 - pharmaceuticals 260
 - product by process patent protection 223–4
 - burden of proof in infringement cases 224–5
 - subject matter discrimination 13
 - USA–Argentina patent dispute 216–31
 - USA–Brazil patent dispute 232–7
- Patry, W.F. 53
- Pharmaceutical Research and Manufacturers of America (PhRMA) 234
- pharmaceuticals
 - Europe, IP protection and registration 107
 - generic producers 106
 - local production 269–70
 - patents 260

- protection of undisclosed
 - pharmaceutical and agrochemical test data 101–7
- stockpiling 240
 - USA–Argentina patent dispute 215–31
- pharmacy exception 275–6
- piracy 26, 99
- practicing entities, damages 61–3
- Prakash-Canjels, G. 63
- preliminary injunctions, Argentina 225–7
- process patent protection 223–4
- property rules, and liability rules 65
- Provisional Standards Employed by Customs for Uniform Rights Enforcement (SECURE) 25, 29
 - compared to TRIPS 29–34
 - enforcement 30
 - infringing goods 34
 - and right-holders 30–31
 - scope of protection 30
 - standards 29, 30
 - as a threat to developing countries 29
 - TRIPS-plus-plus elements 30
- proximate causation 62
- public interest, and injunctive relief 73–4
- Pugatch, M.P. 281

- Rader, J. 56
- Rangenekar, D. 126
- ‘reasonable royalty’ 64
- ‘reference right’ 106
- regulatory review exception 258–63
 - compared to stockpiling exception 265–70
- Reichenmiller, P. 263
- Reichmann, J.H. 17, 76, 79, 260, 264, 268
- Resource Book on TRIPS 123, 124
- retail differentiation 48
- Ricketson, S. 18, 212, 213
- rights centred approaches 280
- Robertson, M.D. 76
- Robinson, W.C. 51, 57
- Roessler, F. 287
- Roffe, P. 263
- Rome Convention for the Protection of Performers, Producers of Phonograms and Broadcasting Organizations 4, 212
- Russia 84
 - law ‘On the Procedure for Consideration of Appeals by Citizens of the Russian Federation’ 80
- Rwanda, patent exceptions 258
- Ryan, D.F. 52

- Samardzija, M.R. 75
- Santilli, M. 64
- Sarnoff, J.D. 77
- Saudi Arabia
 - accession to WTO 88–9, 90, 92
 - administration of law 115
- ‘Scenarios for the Future’ (EPO) 270
- Schneider, M. 26
- Schoenhar, P.M. 53
- Scotchmer, S. 288
- Scott Oliver, L. 55
- SECURE *see* Provisional Standards Employed by Customs for Uniform Rights Enforcement (SECURE)
- Sell, S. 5
- Senftleben, M. 200, 272, 276, 277, 278, 279
- Seychelles 84
- Shapiro, C. 51, 68
- Shashikant, S. 39
- small/vulnerable island economies 83
- Spain 126
- Spenneman, C. 128, 264
- Sterk, S.E. 65
- Stiefel, A. 65
- Stockholm Conference 199, 201
- stockpiling exception 262
 - compared to regulatory review exception 265–70
- Story, J. 48, 49
- Sullivan, J. 213
- Swiss Patents Act 262

- Tanzania, patent exceptions 258
- technological developments, and patent rules 270
- technology transfer 5, 278
- ‘terroir’ 126

- test data
 - impact of *Canada – Patent Protection of Pharmaceuticals* 263–5
 - protection against unfair commercial use 230–31
- Thomas, J.R. 263
- Thrumm, N. 280
- Timmermans, K. 264
- Tonga 107, 111
 - accession to WTO 110
 - data protection 105, 106
 - stand-still principle 111
- trade retaliation 5
- Trade-related Aspects of Intellectual Property Rights (TRIPS) Agreement
 - Active Pharmaceutical Ingredients (SPI) 43
 - applicability of GATT jurisdiction to interpretation 3–23
 - Article 1 124
 - Article 2 284
 - Article 3 7, 286, 287
 - Article 4 7
 - Article 6 7
 - Article 7 278, 279
 - Article 13 213, 276
 - scope of the three-step test 200–203, 213
 - Article 13 special cases 202–3
 - Article 16 134
 - Article 17 276
 - Article 22 124
 - Article 23 125
 - Article 24 125, 134
 - Article 27 21, 228, 232, 234, 235, 239, 240, 267
 - anti-discrimination provision 234, 269, 271
 - interpretation 14–15
 - patentability criteria 228–9
 - Article 27.1, applicability to Article 30 exceptions 253–5
 - Article 28 222, 232, 234, 235, 240–41, 267
 - application in regulatory review exception case 246–7
 - application in stockpiling exception case 242–3
 - Article 30 14, 242, 266–7
 - application in regulatory review exception case 246–7
 - application in stockpiling exception case 242–3
 - legitimate interests 249–52
 - limited exceptions 244–6
 - normal exploitation 247–9
 - object and purpose 243–4
 - three-step test 270–71, 272–3, 276
 - Article 31(k) 218–19
 - Article 34 224–5
 - Article 39 101–7, 230, 264
 - Article 44 58, 59, 60, 64
 - Article 45 58, 64
 - Article 46 36
 - Article 50 225–6
 - Article 51 26, 108
 - Article 52 26–7
 - Article 54, Notice of Suspension 27
 - Article 55, suspended goods 27
 - Article 58 27
 - authority of customs administrations 27
 - Article 59, remedies for right-holders 27
 - Article 60, exceptional circumstances 27–8
 - Article 61 97–8, 99–100, 108
 - Article 62 111
 - Article 65 91, 110, 220, 230
 - Article 70 220–21, 222, 229–30
 - balancing principles 10
 - and Berne Convention 197–8
 - border measures 25–8
 - members' obligations 26
 - commitments for full implementation 90
 - compared to SECURE 29–34
 - compared to UPU Resolution 40 36–7
 - copyright, three-step test 191
 - dispute settlement 215–36
 - domestic policy flexibility for injunctive relief 57–60
 - enforcement authorities 60
 - exceptions to exclusive rights 21–3
 - flexibilities 5, 78
 - full implementation 93
 - geographical indications 122, 123–7

- built-in agenda 128
- disputes 128–30
- lack of most favoured nation
 - exception 17–19
- minimum standards 6, 7–11
 - interpretation 11–14
- national treatment 131–3, 287
- non-discrimination principles 10, 13
- object and purpose 10
- patent protection for pharmaceutical products 91–2
- relationship with GATT 5
- structure compared with GATT and GATS 7–19
- three-step test 21
- see also* World Trade Organisation (WHO)
- trademarks 50, 127, 276, 283, 285
 - and geographical indications 123, 139–40
 - goodwill and reputation 65–6
 - protection of pre-existing trademarks 134–5
 - US – Section 211 Appropriations Act of 1998* 283–97
- traditional knowledge 126
 - in patent law 8
- transition economies 83, 91
- transitional patents, Argentina 229–30
- Treaty in Intellectual Property in Respect of Integrated Circuits 4
- Trebilcock, M.J. 12, 287, 288
- TRIPS-plus-plus standards
 - comparison on IP enforcement at WCO, UPU, and WHO 41
 - on IP enforcement 24
- Ukraine 93, 106, 107
 - administration of law 115
 - Law on Medicines 105
- UNCTAD 258
- UNCTAD–ICTSD 259, 269
- unfair competition 103, 123
 - and geographical indications 124–5
- unilateralism, and national treatment 293–4
- United International Bureaux for the Protection of Intellectual Property (BIRPI) 199
- United States – Measure Affecting Imports of Woven wool shirts and Blouses from India* 242
- United States – US Patents Code* 232
- Universal Postal Union (UPU) 24, 35
 - Resolution 40, 35–7
 - compared to TRIPS 36–7
- Uruguay Round 80, 128
 - Trade-offs 125
- US Measures Affecting the Importation, Internal sale and Use of Tobacco* 294
- US – Anti-dumping Act of 1916* 294
- US – Copyright* 278–9
 - interpretation of term ‘normal’ 279
- US – Section 211 Appropriations Act of 1998* 283–97
 - case of original owners 290–92
 - international harmonization 293
 - mandatory and discretionary legislation, distinction 294–6
 - most favoured nation obligation 293
 - most-favoured-nation obligation 293
 - national treatment principle in AB report 286–96
 - successors-in-interest to original owners 289–90
 - unilateralism 293–4
- US – Section 337* 290
- USA
 - Argentina patent dispute 216–31
 - Brazil patent dispute 232–7
 - and China 99, 100
 - Code of Federal Regulations (CFR) 283
 - compulsory licensing 58
 - Copyright Act
 - business exception 194, 203–4, 205, 206–7, 210–11
 - homestyle exception 194–5, 196, 204–5, 207–9
 - Section 106 193
 - Section 110(5) 142–90
 - and TRIPS 211
 - as a violation of TRIPS 192
 - copyright laws 9
 - copyright Royalty Board 76
 - Court of Appeals for the Federal circuit 49, 50, 51, 53, 54, 73, 76
 - Cuban Assets Control Regulations (CACR) 283, 289

- Fairness in Music Licensing Act (1998) 196
- geographical indications 129, 130
- Hatch-Waxman Act 77, 238
- injunctive relief case law 57–8
- Office of Foreign Assets Control (OFAC) 283, 289, 290, 292, 293, 295
- Omnibus Appropriation Act (1998), Section 211 283–4
- Patent Act (1819) 57
- Special 301 Priority Watch List 234
- Supreme Court 53, 54, 55
- Trading with the Enemy Act (1917) 283
- trial courts, discretionary authority 57
- USPTO 263
- validity, legitimate challenges to 69
- Vanuatu 84
- Vernon, J.A. 77
- Vienna convention, Articles 31 and 32 241–2
- Vienna Convention on the Law of Treaties 9, 247
- Viet Nam 93, 97, 107
 - criminal enforcement of IPR 98–9
 - software and government agencies 109
- Vivas-Engui, D. 128
- Vrins, O. 26
- Wechkin, J.M. 77
- Wegner, H.C. 59
- Weissman, R. 106
- Westkamp, G. 8
- Wetzler, J. 233
- Whitaker, L. 75
- wines and spirits 124, 125
- World Customs Organization (WCO) 24, 28–9
 - SECURE 29–30, 34
- World Health Assembly (WHA) 42
 - ‘Global strategy and plan of action on public health, innovation and intellectual property’ 280
- World Health Organization (WHO) 23, 24, 37
 - IMPACT 37–9
 - comparison of counterfeit medical product and TRIPS 39
 - definition of ‘counterfeit’ 38
- World Intellectual Property Organisation (WIPO) 7, 24
- Copyright Treaty 185, 212
- Development Agenda 213, 281
- exceptions and limitations to copyright 213
- full implementation of TRIPS 93–7
- geographical names 124
- Performers and Phonograms Treaty 212
- and WTO 25
- World Trade Organisation (WTO) 3, 4, 24, 60
 - accession to 85–6
 - Appellate Body 117, 215, 285–6
 - report on *US – Section 211 Appropriations Act of 1998* 286–96
 - background 60–61
 - commitment beyond the full implementation of TRIPS 101
 - commitments of acceding countries on IPRs 87–114
 - dispute on EC – Protection of Trademarks and Geographical Indications for Foodstuffs (EC – GI) 122
 - Dispute Settlement Body 19, 97, 191, 215, 237
 - findings of panel 210–11
 - panel report on copyright dispute 191
 - business exception 191
 - homestyle exception 191
 - implementation 211–12
 - Dispute Settlement Body (DSB), *US – Section 211 Appropriations Act of 1998* 283
 - Dispute Settlement Understanding (DSU) 5, 9, 19, 23, 117, 216
 - enforcement of commitments under accession process 117–19
 - full implementation of TRIPS, as understood by the Working Party on Enforcement 97–100
 - General Council 215
 - implementation of TRIPS 90–93

- LDCs, accession 109–14
- legislative practices and
 - administration of laws 114–15
- membership 81–2
- Ministerial conference 215
- new accession procedures 82
 - and recent developments 83–7
- original members 81–2
- result based IP enforcement
 - obligation 107–9
- review of administrative decisions
 - and right of appeal, China 115–16
- stand-still principle 111
- transition period for TRIPS
 - implementation 90–93
- USA–Argentina patent dispute 216–31
- burden of proof in process
 - infringement cases 224–5
- compulsory licenses 218–19
- exclusive marketing rights 219–22
- import restrictions 222–3
- mutually agreed solution 217–18
- patentability of micro-organisms 227–9
- preliminary injunctions 225–7
- product by process patent
 - protection 223–4
- protection of test data against
 - unfair commercial use 230–31
- transitional patents 229–30
- USA–Brazil patent dispute 232–7
 - mutually agreed solution 232–3
- and WIPO 25
- Working Party Report documents 88

